Swedish Orphan Biovitrum AB (publ) - BIOVF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$25.00
+0 (0.00%)

This chart shows the closing price for BIOVF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Swedish Orphan Biovitrum AB (publ) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIOVF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIOVF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Swedish Orphan Biovitrum AB (publ) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $25.00.

This chart shows the closing price for BIOVF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Swedish Orphan Biovitrum AB (publ). This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/17/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/15/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/13/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/12/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/25/2023Morgan StanleyBoost TargetSEK 280
7/20/2023Royal Bank of CanadaBoost TargetSEK 320
7/14/2023HSBCInitiated CoverageBuy
6/6/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight
4/14/2023Nordea Equity ResearchUpgradeHold ➝ Buy
4/13/2023Royal Bank of CanadaUpgradeSector Perform ➝ Outperform
12/5/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight
9/28/2022Royal Bank of CanadaInitiated CoverageSector Perform
8/1/2022Morgan StanleyInitiated CoverageOverweight
4/14/2022DNB MarketsUpgradeHold ➝ Buy
2/22/2022BarclaysBoost TargetSEK 210 ➝ SEK 215
2/11/2022Nordea Equity ResearchUpgradeHold ➝ Buy
10/27/2021Pareto SecuritiesDowngradeBuy ➝ Hold
7/23/2021BarclaysSet TargetEqual Weight$20.00
7/22/2021Pareto SecuritiesUpgradeHold ➝ Buy
7/21/2021Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
5/5/2021SEB Equity ResearchDowngradeBuy ➝ Hold
5/5/2021SEB EquitiesDowngradeBuy ➝ Hold
5/5/2021DNB MarketsDowngradeBuy ➝ Hold
4/20/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold
3/2/2021BarclaysReiterated RatingOverweight ➝ Equal Weight
2/24/2021BarclaysDowngradeOverweight ➝ Equal Weight
2/19/2021DanskeDowngradeBuy ➝ Hold
7/22/2020BarclaysUpgradeEqual Weight ➝ Overweight
6/19/2020BarclaysUpgradeUnderweight ➝ Equal Weight
7/18/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
(Data available from 4/12/2019 forward)

News Sentiment Rating

0.76 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/15/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/15/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/14/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/14/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/13/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/12/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/13/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/12/2024

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

Swedish Orphan Biovitrum AB (publ) logo
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to treat paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.
Read More

Today's Range

Now: $25.00
Low: $25.00
High: $25.00

50 Day Range

MA: $25.67
Low: $23.32
High: $27.79

52 Week Range

Now: $25.00
Low: $18.35
High: $27.79

Volume

N/A

Average Volume

45 shs

Market Capitalization

N/A

P/E Ratio

34.72

Dividend Yield

N/A

Beta

0.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Swedish Orphan Biovitrum AB (publ)?

The following Wall Street research analysts have issued stock ratings on Swedish Orphan Biovitrum AB (publ) in the last twelve months: HSBC Holdings plc, Morgan Stanley, Nordea Equity Research, and Royal Bank of Canada.
View the latest analyst ratings for BIOVF.

What is the current price target for Swedish Orphan Biovitrum AB (publ)?

0 Wall Street analysts have set twelve-month price targets for Swedish Orphan Biovitrum AB (publ) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Swedish Orphan Biovitrum AB (publ) in the next year.
View the latest price targets for BIOVF.

What is the current consensus analyst rating for Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ) currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BIOVF will outperform the market and that investors should add to their positions of Swedish Orphan Biovitrum AB (publ).
View the latest ratings for BIOVF.

What other companies compete with Swedish Orphan Biovitrum AB (publ)?

How do I contact Swedish Orphan Biovitrum AB (publ)'s investor relations team?

Swedish Orphan Biovitrum AB (publ)'s physical mailing address is Tomtebodavagen 23 A Solna, Stockholm V7, SE-112 76. The company's listed phone number is (468) 697-2000 and its investor relations email address is [email protected]. The official website for Swedish Orphan Biovitrum AB (publ) is www.sobi.com. Learn More about contacing Swedish Orphan Biovitrum AB (publ) investor relations.